Integrating "Physical Intelligence" to Accelerate Next-Gen Drug Validation and Bio-AX Revolution SANTA CLARA, CA, ...

Gossamer Bio's experimental treatment failed to significantly improve exercise capacity in patients with a rare lung ...

A series of converging advances in bio-implant technology, from brain-spine interfaces to lab-grown spinal tissue, is ...

Gossamer Bio will be reporting the outcome of a late-stage study in pulmonary arterial hypertension. Here's what to know.

New workflow validated on Dynamic Devices Lynx® delivers scalable plasmid DNA extraction from Midi to Maxi-prep volumes ...

Gossamer Bio's phase three study of its seralutinib drug for Pulmonary Arterial Hypertension did not meet the statistical threshold for its primary endpoint. Shares fell 82% to 38 cents in premarket ...

Gossamer Bio (NASDAQ:GOSS) shares dropped roughly 80% on Monday after the company announced that its investigational therapy seralutinib failed to achieve the primary endpoint in the Phase 3 PROSERA ...

Seasoned Life Sciences Executive Joins to Lead Operations and Scale Lahjavida’s Dye-Drug Conjugate Platform COLORADO ...

Collaborations with top automation, sequencing, & technology partners highlight Omega's commitment to advancing ...

Syndex Bio, a biotechnology company advancing next‑generation molecular diagnostics, today announced the introduction of its proprietary mcPCR ™ (methyl‑copying PCR) platform at the Advances in Genome ...